|
|
|
|
|
|
Sponsored by: |
Novartis |
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00035165 |
This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause melanoma.
Condition | Intervention | Phase |
Melanoma |
Drug: epothilone b |
Phase II |
MedlinePlus related topics: | Cancer Melanoma |
Drug Information available for: | Epothilone B Ixabepilone |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Melanoma |
Ages Eligible for Study: | 18 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
The following patients may be eligible for this study:
Exclusion Criteria
The following patients are not eligible for this study:
United States, Florida | |||||
H. Lee Moffitt Cancer Center and Research Institute | |||||
Tampa, Florida, United States, 33612 | |||||
United States, North Carolina | |||||
Duke University Medical Center | |||||
Durham, North Carolina, United States, 27710 | |||||
United States, Oklahoma | |||||
Oklahoma Oncology, Inc. | |||||
Tulsa, Oklahoma, United States, 74104 | |||||
United States, Pennsylvania | |||||
UPMC Health Systems | |||||
Pittsburgh, Pennsylvania, United States, 15213 |
Novartis |
Study Chair: | Novartis | Novartis |
Study ID Numbers: | CEPO906A2206 |
First Received: | May 2, 2002 |
Last Updated: | August 15, 2006 |
ClinicalTrials.gov Identifier: | NCT00035165 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
|